Why diversity in clinical trials is important. And how you can help!

By FYH News Team

Published on May 21, 2022

[ad_1]

A lack of diversity in clinical trials is a serious issue with significant health implications. People of color, including Asian American and other racial groups, make up 40% of the general population in the U.S. Yet clinical trial participation skews heavily White—in some cases, 80% to 90%
Janssen Pharmaceutical is a paid…

Read Full Story

If the content contained herein violates any of your rights, including those of copyright, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com

Asian American

Drug Administration-approved

Janssen Pharmaceutical

The Morning

U.S.

Top News

comments

Load app to read more comments

[ad_2]

Source link

Features

Download and distribute powerful vaccination QI resources for your community.

MCED tests use a simple blood draw to screen for many kinds of cancer at once.

FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.

Discover an honest look at our Medicare system.

ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.